Charting the path from pioneering
biology to impactful therapeutics.

We are a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.

Learn More

Featured

SRA737+LDG preclinical activity with immunotherapy presented at AACR 2019

Late-breaking oral presentation by Dr. Lauren Byers, MD Anderson, reports preclinical data for Chk1 inhibitor SRA737+LDG (non-cytotoxic low dose gemcitabine) with immunotherapy in IO-refractory small cell lung cancer.

The DNA Damage Response (DDR) Network

DNA Damage Response (DDR) network is a system of cellular pathways that monitor, signal and repair DNA damage. In cancer cells, replication stress induced by oncogenes (e.g., MYC or RAS), genetic mutations in DNA repair machinery (e.g., BRCA1 or FANCA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or ATM) or other genetic alterations result in persistent DNA damage and genomic instability. Targeted inhibition of the remaining components of the DDR network, such as by SRA737 or SRA141, may be synthetically lethal to cancer cells and have utility as a monotherapy or in combination with other therapeutic modalities across a range of tumor indications.